• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » GSK to establish global vaccines R&D center in the U.S.

GSK to establish global vaccines R&D center in the U.S.

April 6, 2015
CenterWatch Staff

GlaxoSmithKline is establishing a new global center for vaccines R&D in Rockville, Md. The site will become one of three global vaccines R&D centers for GSK, complementing the company’s existing global R&D center in Rixensart, Belgium and in Siena, Italy, a site GSK acquired from Novartis last month.

The new center will expand GSK’s efforts to discover and develop novel vaccines across a range of pressing public health threats, including those relevant to the U.S. It will consolidate vaccines R&D activities currently conducted at other GSK sites, including in Philadelphia and Cambridge, Mass., into one centralized location. Key late stage development programs, as well as vaccine discovery and new platform technology development, will be led from Rockville.

The Rockville site, acquired by GSK in 2012, offers proximity to vaccines collaborators and key public health stakeholders. GSK anticipates site operations for vaccines to begin in Rockville as early as September.

This move follows GSK’s acquisition of Novartis’ vaccines business as part of the companies’ major three-part transaction that closed in March. GSK’s and Novartis’ vaccines R&D organizations are highly complementary, bringing together respective experience in virology and bacterial infection.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing